戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 n and activation, or phosphorylation, of the epidermal growth factor receptor kinase.
2 ow affinity of this radiotracer to wild-type epidermal growth factor receptor kinase.
3 wly developed, irreversible inhibitor of the epidermal growth factor receptor kinase.
4  Eps15 is a phosphorylation substrate of the epidermal growth factor receptor kinase.
5 ylated and thereby activated in vitro by the epidermal growth factor receptor kinase.
6    Lapatinib is a dual inhibitor of HER2 and epidermal growth factor receptor kinases.
7 activation by beta(3)AR depends upon Src and epidermal growth factor receptor kinase activities and i
8                       Finally, inhibition of epidermal growth factor receptor kinase activity did not
9 lar endothelial growth factor receptor-2 and epidermal growth factor receptor kinase activity.
10 ealed that such arsenite action depends upon epidermal growth factor receptor kinase activity.
11                        KRC is a substrate of epidermal growth factor receptor kinase and P34cdc2 kina
12                                Inhibitors of epidermal-growth-factor-receptor kinase and calcium-acti
13 tyrosine kinases, including JAK1, JAK3, HCK, epidermal growth factor receptor kinase, and insulin rec
14                                              Epidermal growth factor receptor-kinase, c-src kinase, a
15 13-residue peptide sequence (Y1173) from the epidermal growth factor receptor/kinase (EGFR) at which
16 Ischemic PC had no effect on the activity of epidermal growth factor receptor kinases, either at 5 or
17 ) for noninvasive detection of active mutant epidermal growth factor receptor kinase-expressing non-s
18                  These off-target effects of epidermal growth factor receptor kinase inhibition sugge
19  the FER kinase inhibitor crizotinib and the epidermal growth factor receptor kinase inhibitor canert
20 ortmannin (IC50 approximately 25 nmol/L) and epidermal growth factor receptor kinase inhibitor gefiti
21         Internalization was prevented by the epidermal growth factor receptor kinase inhibitor tyrpho
22  kinase C inhibitor), and tyrphostin AG1478 (epidermal growth factor receptor kinase inhibitor).
23                                              Epidermal growth factor receptor kinase inhibitor, gefit
24 r receptor, with local administration of the epidermal growth factor receptor kinase inhibitors AG147
25                                  FGF or EGF (epidermal growth factor) receptor kinase inhibitors have
26               Furthermore, inhibitors of the epidermal growth factor receptor kinase, Janus kinase-2
27 holipase C-beta, protein kinase A, c-Src and epidermal growth factor receptor kinase pathways or inhi
28 e used purified Stat3 alpha, Stat3 beta, and epidermal growth factor receptor kinase produced in reco
29 t PV antibody binding leads to activation of epidermal growth factor receptor kinase, Src, p38 MAPK,
30           Furthermore, the inhibition of the epidermal growth factor receptor kinase with low doses o

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。